Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Symptoms and General Pathology

Rare Diseases

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Congenital Abnormalities

Neoplasm, Residual

Lymphoma

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Neoplastic Processes

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Lymphosarcoma

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Anti-Infective Agents

Antirheumatic Agents

Dermatologic Agents

Reproductive Control Agents

Micronutrients

Hematinics

Vitamins

Dexamethasone

Cytarabine

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Methotrexate

Prednisone

Vincristine

Daunorubicin

Dexamethasone acetate

Pegaspargase

Mercaptopurine

Asparaginase

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Antimetabolites

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antiviral Agents

Folinic Acid

Folate

Vitamin B9

All patients deemed eligible to intensive protocol of treatment are going to be included as sole group. There is no intervention or control group in this trial.

Vincristin

Peg-asparaginase

MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29

Intrathecal Suspension

75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60

30 mg/m2 D36 to D63 and D1 to D56 of consolidation

Graziela Silva

Bruna Moraes, MSc

Wellington F Silva, MD PhD

Eduardo M Rego, MD PhD

In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.

Notably, pediatric regimens for adult acute lymphoblastic leukemia (ALL) have resulted in better long-term outcomes, especially in the Philadelphia-negative counterpart. These regimens are essentially based on higher cumulative doses of asparaginase and the use of less myelotoxic agents, applying allogeneic transplantation only for high-risk ALL subsets. Recent metanalysis encompassing 27 clinical trials demonstrated an improved prognosis when these regimens are adopted. In adults, incorporation of these regimens has been hampered by a perception of higher toxicity and a more complex design, especially with asparaginase. Remarkably, this drug might bring side effects not usually seen with other cancer drugs, such as thrombosis, liver, and pancreatic toxicities. In addition, the incorporation of minimal residual disease (MRD) monitoring throughout the treatment protocol in a scheduled and standardized manner is considered paramount in the contemporary ALL treatment. Treating adult patients with acute leukemia under prospective studies allows accurate data collection and positively impacts the disease prognosis, creating a cooperative scientific environment. In Brazil, few data are available on the clinical- laboratory characteristics of ALL in adults and their outcomes under a standardized treatment protocol. Few single-center reports point to a worse overall survival rate when compared to developed countries. There is great heterogeneity across the centers regarding the treatment regimens and genetic/MRD assessment. In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. At the diagnosis, a genetic characterization encompassing conventional karyotype, fluorescent in-situ hybridization (FISH), and molecular biology in our central laboratory will be performed to classify the cases. Genomic classification will include identifying Philadelphia- like B-cell ALL cases, a recent group of cases with worse prognosis, whose incidence seems higher in Hispanics. In Brazil, there is no study addressing this incidence and, more importantly, evaluating its impact on outcomes under a standardized treatment protocol. MRD analysis will also be centralized to standardize and validate our flow cytometry panel in a homogeneous cohort. Additionally, the investigators plan to assess baseline factors predictive of survival and relapse and those related to major toxicities such as infections, liver toxicity, and thrombosis.

All bone marrow or peripheral blood samples from diagnosis are going to be stored in a registered biobank. From bone marrow, DNA, RNA (Trizol) and mononuclear cryopreserved cells are going to be stored after Ficoll separated centrifugation. From peripheral blood, only DNA/RNA from buffy coat.

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study

cumulative proportion of patients alive (considering the time between the date of diagnosis and death or last follow-up)

time between enrollment in the study and the occurrence of any event: refractoriness after the first two cycles of induction, death or relapse.

proportion of patients who died before the first bone marrow evaluation of response (after induction I)

proportion of patients with bone marrow aspirate with less than 5% blasts and evidence of normal hematopoiesis; CSF without blasts and recovery of peripheral blood (neutrophils≥ 1,000/μL and platelets≥100,000/μL), without the need for transfusion

rate of disease relapse after CR calculated considering death as a competing event.

proportion of patients eligible for the protocol who were able to perform the procedure in their first CR

Servier

Instituto do Cancer do Estado de São Paulo

Principal Investigator

Yanyan Liu, M.D. Ph.D

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.

the incidence of driver gene abnormalities by fixed gene testing technology

the total proportion of patients with complete response (CR) and partial response (PR)

from the date of first patient was included to the date of death by any cause

study data on clinicopathological characteristics related to incidence of driver gene abnormalities

Henan Cancer Hospital

Director

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

DNA mass

Yaying Bai, MSc

Chih-Hsin Yang, PhD

The logical next step is to integrate molecular profiling into the care of all patients with NSCLC.

NSCLC is an area of oncology in which clinicians are beginning to use specific tumor-associated molecular aberrations to assign and/or prioritize targeted therapies for patients. At this early stage, multiple hurdles remain before molecular profiling becomes a routine part of thoracic oncology practice. In particular, to develop specific targeted therapies for patients whose tumors harbor rare mutations, it will be important to identify appropriate candidates, design the appropriate trials, and execute the trials with adequate numbers to achieve the necessary endpoints. Implementation will facilitate realization of the promise of molecularly tailored therapy, which could lead to more effective treatments with fewer side effects.

Genotyping of Non-small Cell Lung Cancer

Genotyping of Non-small Cell Lung Cancer Cells - A Study of Taiwan Lung Cancer Clinical Trial Consortium (TALCC)

To determine the frequency of individual genotyping in cancer cells of advanced non-small cell lung cancer (NSCLC) patients who have participated or will commence the clinical trial.

To determine the frequency with which molecular profiling of a NSCLC patient's tumor by DNA mass spectrometry yields a target against which there is approved or investigational therapeutic regimen.

To determine the response rate according to RECIST, progression-free, and overall survival in patients with advanced NSCLC whose therapy is selected by molecular profile.

National Taiwan University Hospital

Mesothelioma

Mesothelioma, Malignant

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms, Mesothelial

Pleural Neoplasms

Malignant Mesothelioma

Central Nervous System Depressants

Anesthetics

All patient with suspected malignant pleural mesothelioma requiring surgical biopsy after validation in oncologic multidisciplinary board will be included. During a standardized routine procedure of pleural biopsy by mean of general anesthesia and video thoracoscopic approach, 3 - 5 biopsies are realized. During this procedure, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).

PLEURAL BIOCOLLECTION OF MALIGNANT PLEURAL MESOTHELIOMA

Jean-Michel MAURY, MD

Jean Michel MAURY

Malignant pleural mesothelioma (MPM) is a rare pleural cancer, which could be primary or secondary to an asbestos exposure. To enhance our knowledge of this rare disease, an exploration of genetic and tumor mechanism is mandatory. One of the principal difficulty is to harvest sufficient tumour pieces to perform multi-omics analysis. The goal of the SCITH-MESO study is to harvest larges pieces of tumour during a routine surgical procedure of MPM diagnosis by mean of pleural biopsies during VATS surgery. Operating samples will increase a tissue bank collection (CRB).

pleural samples of malignant pleural mesothelioma

Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma

For patients with MPM, blood samples are collected and a piece of biopsy will be used for the constitution of a specific bio collection in the CRB (centre de ressources biologiques).

Hospices Civils de Lyon

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

This cohort included patients with late-stage metastatic breast cancers and their disease progressed after at least two-line treatment.

ctDNA testing was performed for late-stage metastatic breast cancer patients to trace their ctDNA abnormality.

ctDNA testing

Quchang Ouyang, MD

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) application in late-stage breast cancers.

This study aims to evaluate the feasibility of plasma ctDNA mutation spectrum and clonal spectrum in late-stage metastatic breast cancer patients. Meanwhile, this study tries to establish a model of ctDNA subtyping system to evaluate the molecular load of tumor, to evaluate the curative effect comprehensively and to detect the disease progression in advance. In addition, the investigators plan to explore the clonal evolution of ctDNA in patients with progressive disease (PD), and to monitor the changes of tumor heterogeneity from the molecular level, so as to provide reference for the analysis of drug sensitivity.

Peripheral blood lymphocytes (PBL) and plasma

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

Clinical Application of Circulating Tumor DNA (ctDNA) to Monitor the Molecular Tumor Burden in Patients With Late-stage Breast Cancer

The dynamic change of the frequency spectrum of ctDNA mutation in plasma.

Hunan Cancer Hospital

Fulvestrant

Androgen Receptor Antagonists

Histone Deacetylase Inhibitors

Estrogens

Estrogen Antagonists

Estrogen Receptor Antagonists

Control group includes patients without ctDNA abnormality and patients without druggable ctDNA abnormality.

Case group includes patients with druggable ctDNA abnormality.

Control group

Druggable ctDNA alterations-guided therapy

Case group

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.

This study aims to evaluate the feasibility of plasma ctDNA mutation in guiding late-line treatment for late-stage metastatic breast cancer patients. Meanwhile, this study tries to evaluate the curative effect of ctDNA subtype-guided late-line therapy.

Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer

Clinical Application of Circulating Tumor DNA (ctDNA) to Guided the Late-Line Treatment for Patients With Late-Stage Breast Cancer

The total rate of CR+PR+SD after the completion of two cycles of late-line therapy.

The survival time between the beginning of treatment to death or the progression.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil	NCT05959720	Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti...	Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin	16 Years - 50 Years	Instituto do Cancer do Estado de São Paulo
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma	NCT04263935	Lymphoma Gene Abnormalit...		-	Henan Cancer Hospital
Genotyping of Non-small Cell Lung Cancer	NCT02002117	Non-small Cell ... Gene Abnormalit...	DNA mass	18 Years -	National Taiwan University Hospital
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil	NCT05959720	Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti...	Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin	16 Years - 50 Years	Instituto do Cancer do Estado de São Paulo
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma	NCT04823741	Mesothelioma, M... Gene Abnormalit... Pleural Mesothe...	PLEURAL BIOCOLL...	18 Years - 95 Years	Hospices Civils de Lyon
Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma	NCT04823741	Mesothelioma, M... Gene Abnormalit... Pleural Mesothe...	PLEURAL BIOCOLL...	18 Years - 95 Years	Hospices Civils de Lyon
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer	NCT05079074	Metastatic Brea... Circulating Tum... Gene Abnormalit...	ctDNA testing	18 Years - 70 Years	Hunan Cancer Hospital
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer	NCT05427617	Metastatic Brea... Circulating Tum... Gene Abnormalit...	Control group Case group	18 Years - 70 Years	Hunan Cancer Hospital

Spots Global Cancer Trial Database for gene abnormality